# Abbott to acquire Bigfoot Biomedical

Abbott has agreed to acquire Bigfoot Biomedical, a developer of smart insulin management systems. The transaction is expected to close in Q3 2023; financial terms were not disclosed.

- Type: Acquisition
- Announced: 2023-09-05
- Where: United States
- Status: announced
- Products: Bigfoot Unity smart insulin management system, FreeStyle Libre continuous glucose monitors
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Abbott](https://endata.com/companies/4479.md) (acquirer)
- [Abbott Laboratories](https://endata.com/companies/20171.md) (acquirer)
- [Bigfoot Biomedical](https://endata.com/companies/25600.md) (target)

## Sources

- [abbott.mediaroom.com](https://abbott.mediaroom.com/2023-09-05-Abbott-to-Acquire-Bigfoot-Biomedical,-Furthering-Efforts-to-Develop-Personalized,-Connected-Solutions-for-People-with-Diabetes), 2023-09-05: "The acquisition of Bigfoot Biomedical will combine two leaders in different aspects of diabetes care: continuous glucose monitoring and insulin dosing support."
- [massdevice.com](https://www.massdevice.com/fast-five-abbott-to-acquire-bigfoot-biomedical-zimmer-biomet-makes-handful-of-executive-changes/), 2023-09-07: "Another diabetes acquisition is in the news – this time, Abbott is acquiring Bigfoot Biomedical."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.